Search Write for us Sign in
OpenAI Daily News

Independent news about OpenAI and ChatGPT. Not an OpenAI publication.

Sunday, November 15, 2026Sources checked

Business

This drug-development startup raised about $20 million; now its team builds OpenAI's life-sciences AI; here's what you need to know

The Economic Times

This drug-development startup raised about $20 million; now its team builds OpenAI's life-sciences AI; here's what you need to know

Picture: The Economic Times

OpenAI acquired Ashoka Rajendra's biotech company Orchestra Bio in October 2026. It was founded in 2022 and is based in San Francisco. The platform was founded by Indian American tech entrepreneur Ashoka Rajendra. The aim was to help biopharma teams coordinate the complex process of drug development. After the development, OpenAI stated, We're bringing Orchestra’s team and technology together with Rosalind, our AI models and tools for life sciences research. It was claimed that the aim was to help scientists make discoveries. It was also done to manage the work needed to turn them into treatments that reach patients sooner. The deal meant that it will bring Orchestra Bio's team and technology into OpenAI's life sciences business.

This report was first published by The Economic Times. What you see here is a brief excerpt. The full text is theirs.

Continue reading at The Economic Times

Pass it on X Facebook WhatsApp

More reports on this

Latest in Business

  1. A step toward defining the Standard Model on a lattice

  2. OpenAI and Broadcom's custom AI inference chips could pressure NVIDIA

Everything in Business

Policy & Courts

ChatGPT

  1. Bill Simmons ends ChatGPT deal after fan backlash